Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study

Research output: Contribution to journalJournal articleResearchpeer-review

Jørgen Matz, Claus Graff, Petri J. Vainio, Antero Kallio, Astrid Maria Højer, Johannes J. Struijk, Jørgen K. Kanters, Mads Peter Andersen, Egon Toft

Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).
Original languageEnglish
JournalClinical Drug Investigation
Issue number11
Pages (from-to)799-811
Number of pages13
Publication statusPublished - 2011

    Research areas

  • Adult, Anti-Infective Agents, Arrhythmias, Cardiac, Aza Compounds, Biomarkers, Pharmacological, Dose-Response Relationship, Drug, Double-Blind Method, Electrocardiography, Female, Guidelines as Topic, Heart Rate, Humans, Long QT Syndrome, Male, Naltrexone, Narcotic Antagonists, Placebos, Prospective Studies, Quinolines, Treatment Outcome, Young Adult

ID: 48052162